{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:50:45Z","timestamp":1779907845302,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["APP1027493"],"award-info":[{"award-number":["APP1027493"]}]},{"name":"Australian National Health and Medical Research Council","award":["APP1008473"],"award-info":[{"award-number":["APP1008473"]}]},{"name":"Schizophrenia Research Institute, Australia"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.pnpbp.2014.08.006","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T02:46:23Z","timestamp":1408502783000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A\/2C bindings in rat brains"],"prefix":"10.1016","volume":"56","author":[{"given":"Jiamei","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2014.08.006_bb0005","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1523\/JNEUROSCI.1090-09.2009","article-title":"PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors","volume":"29","author":"Abbas","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0015","first-page":"24","article-title":"Effects of betahistine and of its metabolites on vestibular sensory organs","volume":"21","author":"Botta","year":"2001","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0020","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats","volume":"81","author":"Choi","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0165-6147(00)01688-6","article-title":"Role of 5-HT2C receptors in the control of central dopamine function","volume":"22","author":"Di Matteo","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.neuroscience.2006.02.068","article-title":"Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain","volume":"139","author":"du Bois","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s11064-007-9571-y","article-title":"Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade","volume":"33","author":"du Bois","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0055","series-title":"Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers","author":"FDA","year":"2005"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.05.008","article-title":"Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function","volume":"55","author":"Ferrada","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0065","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0075","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.neuroscience.2009.09.041","article-title":"The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain","volume":"164","author":"Han","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0085","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.pnpbp.2009.04.010","article-title":"Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia\u2014a postmortem study","volume":"33","author":"Kang","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14740330802423234","article-title":"Olanzapine: review of safety 2008","volume":"7","author":"Kantrowitz","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0105","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0110","first-page":"199","article-title":"Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis","volume":"vol. 172","author":"Kuroki","year":"2008"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18773\/austprescr.2011.057","article-title":"Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis","volume":"34","author":"Lambert","year":"2011","journal-title":"Aust Prescr"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2013.08.005","article-title":"Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density","volume":"47","author":"Lian","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0130","doi-asserted-by":"crossref","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0135","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0150","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrn3526","article-title":"The histaminergic network in the brain: basic organization and role in disease","volume":"14","author":"Panula","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0160","series-title":"The Rat Brain in Sterotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","article-title":"The effect of betahistine, a histamine H1 receptor agonist\/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"20","author":"Poyurovsky","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine\u2013betahistine combination","volume":"226","author":"Poyurovsky","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0175","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0180","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.pnpbp.2005.03.019","article-title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment","volume":"29","author":"Reynolds","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0185","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0190","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0200","first-page":"701","article-title":"Betahistine inhibits food intake in rats","volume":"53","author":"Szelag","year":"2001","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment","volume":"297","author":"Tarazi","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0210","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions","volume":"161","author":"Tarazi","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":"Weight gain in antipsychotic-naive patients: a review and meta-analysis","volume":"40","author":"Tarricone","year":"2010","journal-title":"Psychol Med"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0220","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.mp.4001009","article-title":"Significant dissociation of brain and plasma kinetics with antipsychotics","volume":"7","author":"Tauscher","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0225","first-page":"199","article-title":"Weight gain risk factor assessment checklist: overview and recommendation for use","volume":"32","author":"Treuer","year":"2011","journal-title":"Neuroendocrinol Lett"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0230","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.psychres.2008.12.011","article-title":"Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis","volume":"175","author":"Vazquez-Bourgon","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0235","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/7854_2010_44","article-title":"Prefrontal cortical circuits in schizophrenia","volume":"4","author":"Volk","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2014far from the clinic?","volume":"116","author":"Weston-Green","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0245","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pnpbp.2014.08.006_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction","volume":"7","author":"Zhang","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584614001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584614001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:26:25Z","timestamp":1746347185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584614001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":50,"alternative-id":["S0278584614001560"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2014.08.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A\/2C bindings in rat brains","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2014.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}